AustralianSuper Pty Ltd Makes New Investment in Amneal Pharmaceuticals, Inc. $AMRX

AustralianSuper Pty Ltd acquired a new stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 323,443 shares of the company’s stock, valued at approximately $3,238,000. AustralianSuper Pty Ltd owned 0.10% of Amneal Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently made changes to their positions in AMRX. Exchange Traded Concepts LLC purchased a new position in Amneal Pharmaceuticals in the third quarter worth approximately $31,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Amneal Pharmaceuticals by 16.7% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,107 shares of the company’s stock valued at $98,000 after purchasing an additional 1,735 shares in the last quarter. Wealth Enhancement Advisory Services LLC purchased a new stake in shares of Amneal Pharmaceuticals during the 2nd quarter worth $113,000. 111 Capital purchased a new stake in shares of Amneal Pharmaceuticals during the 2nd quarter worth $115,000. Finally, Inceptionr LLC acquired a new position in shares of Amneal Pharmaceuticals during the second quarter worth $115,000. 31.82% of the stock is currently owned by hedge funds and other institutional investors.

Amneal Pharmaceuticals Stock Down 3.0%

NASDAQ:AMRX opened at $13.68 on Friday. The company has a market capitalization of $4.30 billion, a PE ratio of 684.34 and a beta of 1.34. Amneal Pharmaceuticals, Inc. has a 52-week low of $6.68 and a 52-week high of $15.00. The stock’s 50 day moving average price is $12.82 and its 200 day moving average price is $10.83.

Amneal Pharmaceuticals (NASDAQ:AMRX) last issued its quarterly earnings data on Thursday, October 30th. The company reported $0.17 earnings per share for the quarter, beating analysts’ consensus estimates of $0.12 by $0.05. The company had revenue of $784.51 million during the quarter. Amneal Pharmaceuticals had a negative return on equity of 185.60% and a net margin of 0.20%. As a group, sell-side analysts anticipate that Amneal Pharmaceuticals, Inc. will post 0.53 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Ted C. Nark sold 50,000 shares of the stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $11.72, for a total transaction of $586,000.00. Following the completion of the sale, the director owned 291,029 shares in the company, valued at approximately $3,410,859.88. This represents a 14.66% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Nikita Shah sold 131,856 shares of the firm’s stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $11.92, for a total value of $1,571,723.52. Following the transaction, the executive vice president directly owned 146,403 shares in the company, valued at approximately $1,745,123.76. This represents a 47.39% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 231,856 shares of company stock worth $2,743,724. 26.56% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of analysts have weighed in on the company. Barclays started coverage on Amneal Pharmaceuticals in a research note on Monday, December 8th. They issued an “overweight” rating and a $15.00 price target on the stock. Weiss Ratings reissued a “hold (c)” rating on shares of Amneal Pharmaceuticals in a research report on Wednesday, January 21st. Piper Sandler reaffirmed an “overweight” rating and issued a $13.00 price target (up from $11.00) on shares of Amneal Pharmaceuticals in a report on Friday, October 31st. Finally, Truist Financial set a $15.00 price target on shares of Amneal Pharmaceuticals in a research note on Wednesday, January 7th. Four analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $13.80.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.